ProCE Banner Activity

CE / CME

Putting Patients First in Moderate to Severe Ulcerative Colitis

Clinical Thought
We now have more effective and safe therapeutic options than ever. But which medicine is optimal for a given patient, and how do we choose?

Physicians: maximum of 0.25 AMA PRA Category 1 CreditTM

Nurses: 0.25 Nursing contact hour

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.

Share

Faculty

Raymond K. Cross

Raymond K. Cross, MD, MS

Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Provided by

Provided by the American Gastroenterology Association.
ProCE Banner

Supporters

This activity is supported by an educational grant from

Pfizer, Inc.

Target Audience

The primary target audience for the activities includes gastroenterologists, nurses, nurse practitioners, and other healthcare providers who treat patients with ulcerative colitis.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recommendations from the latest UC management guidelines regarding next steps for patients with moderate to severely active UC
  • Consider the utility of the latest UC therapies that can better align with patients’ needs for a treatment that is convenient, effective, and safe

Faculty Disclosure

Primary Author

Raymond K. Cross, MD, MS

Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Raymond K. Cross, MD, MS, has disclosed that he has received consulting fees from AbbVie, Janssen, Samsung Bioepis, and Takeda and fees for non-CME/CE services from Pfizer.

Staff Disclosure

Staff

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no relevant conflicts of interest to report.

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Credit

Physician Continuing Medical Education

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 14, 2020, through December 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program to improve the competence and performance of clinician learners to select effective treatment for patients with moderate to severe ulcerative colitis (UC), including those with difficult-to-treat UC who have failed TNF inhibitor therapy.